ABSTRACT
Rebamipide is a cytoprotеÑtive drug that stimulates the generation of endogenous prostaglandins in the gastric and small intestinal mucosa and accelerates the healing of erosions and ulcers caused by Helicobacter pylori infection and NSAID administration. The major properties of rebamipide include stimulation of prostaglandins and synthesis of muÑus glycoproteins, inhibition of reactive oxygen species, inflammatory cytokines, and chemokines, and suppression of neutrophil activation. This paper shows the ability of rebamipide to enhance the efficiency of therapy for Helicobacter pylori-induced infection, to reduce inflammation, including that after infection eradication, to accelerate ulcer healing, and to prevent the progression of preneoplastic lesions.
Subject(s)
Alanine/analogs & derivatives , Anti-Ulcer Agents/therapeutic use , Helicobacter Infections/drug therapy , Quinolones/therapeutic use , Stomach Ulcer/drug therapy , Alanine/therapeutic use , Gastric Mucosa , Helicobacter pylori , HumansABSTRACT
Using cytometry and an microfluorimetry, we have determined the genome size in Chinese hamster Cricetulus griseus, as well as absolute and relative DNA content of its individual chromosomes and of chromosomes in the transformed Chinese hamster cell lines V-79 RJK and Vebr-5 after prolonged cultivation. It has been shown that the genome size in male and female Chinese hamster is 6.660 and 6.746 pg, respectively. Absolute content of chromosomal DNA of both studied cell lines differed significantly from the content of the corresponding chromosomal DNA of the Chinese hamster normal karyotype. During long-term cellular cultivation, changes in the DNA content of certain chromosomes in both cell lines (generally upward) reached 20-25 %. The level of DNA amplification in the p-arm of chromosome Z6, registered at the beginning of the experiment, in the course of further cellular cultivation (over 20 years) remained stable. The data obtained allow us to conclude that the malignant transformation of cells and subsequent adaptation to the conditions in vitro leads to a profound restructuring of its genome, which affects almost all chromosomes.
Subject(s)
Bone Marrow Cells/metabolism , Chromosomes, Mammalian/chemistry , DNA/chemistry , Fibroblasts/metabolism , Genome Size , Animals , Bone Marrow Cells/cytology , Cell Line, Transformed , Cricetulus , Female , Fibroblasts/cytology , Karyotype , Male , Metaphase , Primary Cell CultureABSTRACT
A total of 85 patients with alcoholic and viral cirrhosis were included in study to assess the prevalence of dysbiosis and its relationship with the severity of disease, and with development of dyspeptic disorders. Intestinal bacterial over-growth was measured by means of a lactulose breath test, fecal flora was cultured under aerobic and anaerobic conditions. Intestinal bacterial overgrowth and colon dysbiosis were determined in 82.4% of patients with equal prevalence in alcoholic and viral cirrhosis. Intestinal dysbiosis was found to be risk factor of increasing cirrhosis severity and liver dysfunction, as well as development of complications of portal hypertension. It was documented, that intestinal dyspepsia syndrome in cirrhotic patients is strongly associated with the presence of gut microflora disorders.
Subject(s)
Dysbiosis/microbiology , Hepatitis, Viral, Human/microbiology , Hypertension, Portal/microbiology , Intestines/microbiology , Liver Cirrhosis/microbiology , Microbiota , Adult , Aged , Breath Tests , Dysbiosis/complications , Dysbiosis/epidemiology , Feces/microbiology , Female , Hepatitis, Viral, Human/complications , Hepatitis, Viral, Human/epidemiology , Hepatitis, Viral, Human/virology , Humans , Hypertension, Portal/epidemiology , Hypertension, Portal/etiology , Liver Cirrhosis/complications , Liver Cirrhosis/epidemiology , Liver Cirrhosis/virology , Male , Middle AgedABSTRACT
Mucrofluorimetric method for the determination of DNA content in individual human chromosomes has been developed. The method is based on a preliminary identification of chromosomes with Hoechst 33258, followed by staining of the chromosomes with Feulgen reaction using Schiffs reagent type ethidium bromide-SO2, then measuring the fluorescence intensity of the chromosomes using an image analyzer. The method allows to determine the DNA content of individual chromosomes with accuracy up to 4.5 fg. DNA content of individual human chromosomes, their p-and q-arms as well as homologous chromosomes were measured using the developed method. It has been shown that the DNA content in the chromosomes of normal human karyotype is unstable. Fluctuations in the DNA content in some chromosomes can vary 35-40 fg.
Subject(s)
Chromosomes, Human/ultrastructure , DNA/ultrastructure , Fluorometry/methods , Molecular Imaging/methods , Bisbenzimidazole , Chromosome Banding , Ethidium/chemistry , Flow Cytometry , Fluorescence , Humans , KaryotypingABSTRACT
This article describes meteospazmil clinical effectiveness in problem of abdominal pain syndrome and flatulence reduction at IBS and gastrointestinal diseases that are attended with secondary colon motor disorders.
Subject(s)
Colon/drug effects , Gastrointestinal Agents/therapeutic use , Gastrointestinal Motility/drug effects , Irritable Bowel Syndrome/drug therapy , Propylamines/therapeutic use , Abdominal Pain/drug therapy , Abdominal Pain/etiology , Abdominal Pain/physiopathology , Adolescent , Adult , Colon/physiopathology , Female , Flatulence/drug therapy , Flatulence/etiology , Flatulence/physiopathology , Gastrointestinal Agents/administration & dosage , Humans , Irritable Bowel Syndrome/complications , Irritable Bowel Syndrome/physiopathology , Male , Middle Aged , Propylamines/administration & dosage , Treatment Outcome , Young AdultABSTRACT
The aim of the study was to assess the expediency of prescription and efficiency of bismuth tri-potassium di-citrate in different therapeutic schemes for the management of irritable bowel syndrome (IBS) dominated by diarrhea. The open prospective study of de-nol efficacy and safety included 30 patients with this disorder allocated to 2 groups. Patients of the main group (n=20) were given 120 mg of de-nol thrice daily in combination with meteospasmyl (a spasmolytic and antifoaming agent). Control patients (n=10) received aluminium phosphate with meteospasmyl (1 capsule thrice daily). Duration of the treatment was 3 weeks. Therapeutic efficiency was assessed from the dynamics of abdominal pain syndrome, stool frequency, properties of faeces, results of their microscopic and microbiological studies, lactulose breath hydrogen test, rectoromanoscopy with rectal mucosal biopsy, and hepatic biochemical test. Before the study, all patients had abdominal pain, diarrhea, meteorism, altered composition of fecal bacteria, their excessive growth in the intestines, and morphological signs of chronic inflammation. Bacterial activity was recorded in 80 and 40% of the patients of the respective groups. By the end of therapy, abdominal pain was eliminated in 90 and 60%, meteorism was absent in 80 and 40%, diarrhea in 75 and 50%, excessive bacterial growth in small intestine in 75 and 30%, changes of fecal microflora persisted in 20 and 70%, histological signs of active mucosal inflammation remained in 40 and 85.7% of the patients of the main and control groups respectively. It is concluded that all patients with irritable bowel syndrome and diarrhea show altered composition of intestinal microflora, morphological signs of moderate chronic inflammation of intestinal mucosa. Most of them have apparent bacterial activity. Treatment with de-nol and spasmolytics for 3 weeks effectively eliminated clinical manifestations of the disease, restored normal composition of intestinal microflora, normalized faeces properties, and resolved active inflammation.
Subject(s)
Anti-Infective Agents/therapeutic use , Diarrhea/drug therapy , Irritable Bowel Syndrome/drug therapy , Organometallic Compounds/therapeutic use , Adolescent , Adult , Anti-Infective Agents/administration & dosage , Bismuth , Diarrhea/diagnosis , Diarrhea/etiology , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Irritable Bowel Syndrome/complications , Irritable Bowel Syndrome/diagnosis , Male , Middle Aged , Organometallic Compounds/administration & dosage , Propylamines/administration & dosage , Propylamines/therapeutic use , Prospective Studies , Treatment Outcome , Young AdultSubject(s)
Pancreas , Pancreatitis, Chronic , Abdominal Pain/drug therapy , Analgesics, Non-Narcotic/therapeutic use , Enzyme Inhibitors/therapeutic use , Exocrine Pancreatic Insufficiency/drug therapy , Histamine H1 Antagonists/therapeutic use , Humans , Lipase/administration & dosage , Lipase/therapeutic use , Pancreas/drug effects , Pancreas/enzymology , Pancreas/metabolism , Pancreatitis, Chronic/diet therapy , Pancreatitis, Chronic/drug therapy , Pancreatitis, Chronic/metabolism , Trypsin/administration & dosage , Trypsin/therapeutic useSubject(s)
Helicobacter Infections , Helicobacter pylori , Liver Cirrhosis/complications , Stomach Diseases , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Drug Therapy, Combination , Female , Gastrointestinal Agents/administration & dosage , Gastrointestinal Agents/therapeutic use , Helicobacter Infections/complications , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Helicobacter pylori/isolation & purification , Humans , Liver Cirrhosis/epidemiology , Male , Stomach Diseases/complications , Stomach Diseases/drug therapy , Stomach Diseases/epidemiology , Stomach Diseases/microbiologyABSTRACT
AIM: To study effects of the probiotic bifiform on efficacy of Helicobacter pylori (HP) eradication in patients with chronic gastritis and ulcer disease. MATERIAL AND METHODS: A total of 98 patients with verified HP infection were divided into two groups. The study group received a week three-component anti-HP therapy+a probiotic. The control group received the same treatment without the probiotic. All the patients were tested for HP before the treatment and one month after the end of the treatment. Cell composition of duodenal mucosa (DM), tissue proinflammatory cytokines, secretory immunoglobulin A (sIgA) in coprofiltrates, serum IgA, IgM, IgG, phagocytic parameters and copromicrobiology were studied. RESULTS: HP eradication rate in the study group was higher than in the control group (89.1 vs 63.5, respectively, p < 0.05). After the treatment, patients of the study group had lower rates of side effects, impaired intestinal biocenosis, tissue cytokines levels but higher concentration of plasmatic cells in CO and cIgA in coprofiltrates. CONCLUSION: The addition of probiotic bifiform to the standard three-component antihelicobacter scheme of the treatment raises its efficacy and is promising treatment of HP. Mechanisms of a potentiating action of the probiotic are related to enhancement of antibacterial activity of local immune reactions.
Subject(s)
Bifidobacterium , Helicobacter Infections/drug therapy , Helicobacter pylori , Probiotics/therapeutic use , Adolescent , Adult , Anti-Bacterial Agents/therapeutic use , Antibodies, Bacterial/immunology , Female , Follow-Up Studies , Gastric Mucosa/microbiology , Gastritis/drug therapy , Gastritis/microbiology , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Helicobacter pylori/immunology , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Stomach Ulcer/drug therapy , Stomach Ulcer/microbiology , Treatment OutcomeABSTRACT
The purpose of this study is to assess the efficiency of the anti-ulcer therapy taking into account the economic aspects of treatment. We have examined 708 HP-positive(+) patients with stomach ulcers (SU) and duodenal ulcers (DU). Various schemes of anti-helicobacter and anti-secretory therapy were administered to them. Positive dynamics of some clinical data (local palpatory tenderness and abdominal wall resistance) and gastritis (gastroduodenitis) activity was discovered in all groups of patients. The cost of the treatment was determined with the help of marketing studies by taking the lowest price of drugs. There were no statistically reliable differences found groups of traditional treatment regimens by both results of HP eradication and the cost of eradicative and anti-secretory therapy. All drugs under study are highly effective for rapid relief of symptoms at an exacerbation of stomach ulcer associated with HP as well as the decrease of gastritis (gastroduodenitis) activity. It is possible to recommend them for both eradicative therapy and prolonged treatment.
Subject(s)
Anti-Ulcer Agents/therapeutic use , Ulcer/drug therapy , Adult , Aged , Aged, 80 and over , Anti-Ulcer Agents/economics , Cost-Benefit Analysis , Duodenal Ulcer/drug therapy , Female , Gastritis/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Stomach Ulcer/drug therapy , Time Factors , Treatment OutcomeABSTRACT
Within 1968-1997 the authors studied the steps of introduction of the achievements of the medical science, technology and pharmacology to therapy of exacerbations and complications of peptic ulcer (PU). The scientific and practical value of endoscopic, histological, biochemical and bacteriological examinations in the improvement of the methods of pharmacotherapy of exacerbations and complications of PU was shown. Three phases of the PU development were indicated by the clinical signs and results of esophagogastroduodenoscopy, target biopsy and histological examinations. These data and available scientific achievements were assumed as a basis for the design of optimal drug combinations and their introduction to the medical practice. The use of such combinations made it possible to prevent relapses and life-threatening complications of the disease in the overwhelming majority of the patients. The best results of the pharmacotherapy were recorded in the years (1988-1997) when the drug combinations began to be used. The combinations provided eradication of Helicobacter pylori in the gastroduodenal mucosa and it was proved that in all the patients with PU and the relapsing lesions in the duodenum and in the overwhelming majority of the patients with gastric ulcer the disease developed at the background of chronic active gastroduodenitis associated with H.pylori. The success of the pharmacotherapy in the patients with PU was due to the use of the rational combinations of antibacterial and antisecretory agents.
Subject(s)
Ambulatory Care/standards , Drug Therapy/standards , Outpatient Clinics, Hospital , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Drug Therapy, Combination , Helicobacter Infections/drug therapy , Humans , Moscow , Peptic Ulcer/drug therapy , Time FactorsABSTRACT
453 patients with ulcer located in the duodenal bulb and pyloric part of the stomach in the presence of Helicobacter pylori were examined before and followed up after hospital treatment of the ulcer. The authors findings support the importance of maintenance with current antisecretory drugs and on-demand therapy as well as of combined antibacterial therapy against Helicobacter pylori. Adequate chemotherapy in the ulcer exacerbation was able to reduce the number of recurrences and complications.